Use of Bevacizumab and Ranibizumab for Wet Age-Related Macular Degeneration: Influence of CATT Results and Introduction of Aflibercept.
Am J Ophthalmol. 2019.
PMID: 31100217
Free PMC article.
Search Page
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 2011 | 3 |
| 2012 | 6 |
| 2013 | 12 |
| 2014 | 14 |
| 2015 | 10 |
| 2016 | 9 |
| 2017 | 4 |
| 2018 | 3 |
| 2019 | 3 |
| 2020 | 6 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 4 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 0 |
Search Results
69 results
Results by year
Citations
1
article
found by citation matching
Search results
Page 1
Ranibizumab and bevacizumab for neovascular age-related macular degeneration.
N Engl J Med. 2011 May 19;364(20):1897-908. doi: 10.1056/NEJMoa1102673. Epub 2011 Apr 28.
N Engl J Med. 2011.
PMID: 21526923
Free PMC article.
Clinical Trial.
BACKGROUND: Clinical trials have established the efficacy of ranibizumab for the treatment of neovascular age-related macular degeneration (AMD). In addition, bevacizumab is used off-label to treat AMD, despite the absence of similar supp …
BACKGROUND: Clinical trials have established the efficacy of ranibizumab for the treatment of neovascular age-related …
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: Two-Year Results.
Ophthalmology. 2020 Apr;127(4S):S135-S145. doi: 10.1016/j.ophtha.2020.01.029.
Ophthalmology. 2020.
PMID: 32200813
Clinical Trial.
PARTICIPANTS: Patients (n = 1107) who were followed up during year 2 among 1185 patients with neovascular age-related macular degeneration who were enrolled in the clinical trial. INTERVENTIONS: At enrollment, patients were assigned to 4 treatment grou …
PARTICIPANTS: Patients (n = 1107) who were followed up during year 2 among 1185 patients with neovascular age-related macul …
Ranibizumab for age-related macular degeneration.
Expert Opin Biol Ther. 2012 Mar;12(3):371-81. doi: 10.1517/14712598.2012.660523. Epub 2012 Feb 6.
Expert Opin Biol Ther. 2012.
PMID: 22309606
Review.
INTRODUCTION: Age-related macular degeneration (AMD) is the leading cause of blindness in patients over 50 years in the developed world. ...Fixed monthly dosing regimens were compared with quarterly dosing regimens in PIER and EXCITE studies and suppor …
INTRODUCTION: Age-related macular degeneration (AMD) is the leading cause of blindness in patients over 50 years …
Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration.
Cochrane Database Syst Rev. 2014 Sep 15;9(9):CD011230. doi: 10.1002/14651858.CD011230.pub2.
Cochrane Database Syst Rev. 2014.
PMID: 25220133
Free PMC article.
BACKGROUND: Neovascular age-related macular degeneration (AMD) is the leading cause of legal blindness in elderly populations of industrialised countries. ...Ranibizumab is approved for intravitreal use to treat neovascular AMD, while bevaciz …
BACKGROUND: Neovascular age-related macular degeneration (AMD) is the leading cause of legal blindness in elderl …
Use of Bevacizumab and Ranibizumab for Wet Age-Related Macular Degeneration: Influence of CATT Results and Introduction of Aflibercept.
Am J Ophthalmol. 2019 Nov;207:385-394. doi: 10.1016/j.ajo.2019.05.011. Epub 2019 May 15.
Am J Ophthalmol. 2019.
PMID: 31100217
Free PMC article.
PURPOSE: To assess whether publication of Comparison of Age-related macular degeneration Treatment Trial (CATT) results and introduction of aflibercept to the marketplace affected intravitreal bevacizumab and ranibizumab utilizatio …
PURPOSE: To assess whether publication of Comparison of Age-related macular degeneration Treatment Trial (CAT …
Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.
Ophthalmology. 2012 Jul;119(7):1388-98. doi: 10.1016/j.ophtha.2012.03.053. Epub 2012 May 1.
Ophthalmology. 2012.
PMID: 22555112
Free PMC article.
Clinical Trial.
PARTICIPANTS: Patients (n = 1107) who were followed up during year 2 among 1185 patients with neovascular age-related macular degeneration who were enrolled in the clinical trial. INTERVENTIONS: At enrollment, patients were assigned to 4 treatment grou …
PARTICIPANTS: Patients (n = 1107) who were followed up during year 2 among 1185 patients with neovascular age-related macul …
Therapeutic efficacy of bevacizumab for age-related macular degeneration: what are the implications of CATT for routine management?
Drugs Aging. 2011 Nov 1;28(11):853-65. doi: 10.2165/11594720-000000000-00000.
Drugs Aging. 2011.
PMID: 21970950
CATT (Comparison of Age-related macular degeneration [AMD] Treatment Trials) examined the efficacy of ranibizumab and bevacizumab for the treatment of neovascular AMD. ...A possible increased risk of adverse events could not be rul …
CATT (Comparison of Age-related macular degeneration [AMD] Treatment Trials) examined the efficacy of …
Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema.
Clin Interv Aging. 2013;8:467-83. doi: 10.2147/CIA.S36811. Epub 2013 Apr 29.
Clin Interv Aging. 2013.
PMID: 23766636
Free PMC article.
Review.
Neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME) are major causes of visual impairment in the elderly population worldwide. ...The CATT and IVAN trials compared the safety and efficacy of ranibizumab …
Neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME) are major causes of v …
Ranibizumab: a review of its use in the treatment of neovascular age-related macular degeneration.
Drugs Aging. 2013 May;30(5):331-58. doi: 10.1007/s40266-013-0077-9.
Drugs Aging. 2013.
PMID: 23539234
Review.
Ranibizumab (Lucentis( )), an inhibitor of all vascular endothelial growth factor (VEGF) A isoforms, is approved for the intravitreal treatment of neovascular age-related macular degeneration (AMD). ...In head-to-head comparisons, aflibercept ad …
Ranibizumab (Lucentis( )), an inhibitor of all vascular endothelial growth factor (VEGF) A isoforms, is approved for the intravitreal …
The role of Aflibercept in the management of age-related macular degeneration.
Expert Opin Biol Ther. 2016;16(5):699-709. doi: 10.1517/14712598.2016.1167182.
Expert Opin Biol Ther. 2016.
PMID: 26982640
Review.
INTRODUCTION: During the past decade, significant advances have occurred in the management of neovascular age-related macular degeneration (NV-AMD). The advent of anti-vascular endothelial growth factor (anti-VEGF) therapy has shifted the treatment goa …
INTRODUCTION: During the past decade, significant advances have occurred in the management of neovascular age-related macul …
Cite